MARKET MAKER TRADING STRATEGIES - FINANCIAL FREEDOM - FOR LIFE! -
ken flagg's Page
Gifts Received
ken flagg has not received any gifts yet
ken flagg's Videos
Ken flagg's Blog
SMF Notes Weekly Roundup On MARCH 11, 2011
- U.S. stocks climbed Friday despite the strongest earthquake to hit Japan in at least 300 years, but the market posted a weekly drop, with the Dow falling 1.03%, the S&P 500 off 1.28% and the Nasdaq down 2.48% for the week.
- For all three markets (DJIA) (COMP) (SPX) , it marked the second down week in the past three weeks.
- The Japanese yen rose more in…
Posted on March 11, 2011 at 8:11pm
SMF Notes HGSI Human Genome: Color on Benlysta approval
HGSI Human Genome: Color on Benlysta approval (25.68 ) -Update-Think Equity notes that the FDA approved Benlysta for the treatment of patients with SLE, making it the first approved medicine for lupus in over 50 years and the only one with an efficacy claim in the label. Firm also notes that based on the absence of efficacious therapy, a broad label and a clean safety profile, they continue to believe that the worldwide market opportunity for Benlysta in lupus… Continue
Posted on March 10, 2011 at 1:49pm
SMF Notes S&P futures vs fair value: -12.70. Nasdaq futures vs fair value: -27.30.
S&P futures vs fair value: -12.70. Nasdaq futures vs fair value: -27.30.
Disappointing data out of Asia and the decision by Moody's to downgrade Spain's debt and issue a negative outlook have dragged down Spain's IBEX to a 1.3% loss. Financials, down 2.0%, are the worst performers there. As such, Banco Santander is a primary source of weakness; it has dropped to a 2.3% loss so that it trades at its lowest level… Continue
Disappointing data out of Asia and the decision by Moody's to downgrade Spain's debt and issue a negative outlook have dragged down Spain's IBEX to a 1.3% loss. Financials, down 2.0%, are the worst performers there. As such, Banco Santander is a primary source of weakness; it has dropped to a 2.3% loss so that it trades at its lowest level… Continue
Posted on March 10, 2011 at 1:48pm
SMF Notes HGSI Human Genome: Stifel is waiting for Benlysta approval (24.92 )
HGSI Human Genome: Stifel is waiting for Benlysta approval (24.92 )Stifel notes that based on discussions with Lupus KOLs, they remain optimistic that the FDA will approve Benlysta by the March 10, 2011 PDUFA date and do not expect major label restrictions for either musculoskeletal/mucocutaneous or racial subgroups. They anticipate U.S. launch in 2Q11 followed by an E.U. launch in 3Q11. They continue to expect Benlysta to generate worldwide 2015 sales of $3.6… Continue
Posted on February 25, 2011 at 7:49pm
© 2012 Created by Hot Stocks.
Comment Wall (1 comment)
You need to be a member of www.SMFHotStocks.com to add comments!
Join www.SMFHotStocks.com